- Non-invasive tests-based risk stratification: Baveno VII and beyond
-
Semmler G, Jachs M, Mandorfer M
- KMID: 2538205
- Clin Mol Hepatol.
- 2023 Jan;29(1):105-109.
- doi: 10.3350/cmh.2022.0361
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
-
Wong YJ, Sharma S, Tosetti G, Qi X, Primignani M
- KMID: 2538222
- Clin Mol Hepatol.
- 2023 Jan;29(1):188-190.
- doi: 10.3350/cmh.2022.0408
-
- CITED
-
- Close
- SHARE
-
- Close
- The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus
-
Yoo JJ, Kim SG
- KMID: 2538204
- Clin Mol Hepatol.
- 2023 Jan;29(1):102-104.
- doi: 10.3350/cmh.2022.0353
-
- CITED
-
- Close
- SHARE
-
- Close
- The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
-
Cho Y, Kim BH, Park JW
- KMID: 2538203
- Clin Mol Hepatol.
- 2023 Jan;29(1):99-101.
- doi: 10.3350/cmh.2022.0321
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
-
Mungmunpuntipantip R, Wiwanitkit V
- KMID: 2538214
- Clin Mol Hepatol.
- 2023 Jan;29(1):168.
- doi: 10.3350/cmh.2022.0328
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
-
Song DS, Chang UI, Yang JM
- KMID: 2538213
- Clin Mol Hepatol.
- 2023 Jan;29(1):165-167.
- doi: 10.3350/cmh.2022.0339
-
- CITED
-
- Close
- SHARE
-
- Close
- Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey
-
Rodrigues SG
- KMID: 2538206
- Clin Mol Hepatol.
- 2023 Jan;29(1):110-112.
- doi: 10.3350/cmh.2022.0414
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
-
Kim TH, Jung YK, Yim HJ
- KMID: 2538217
- Clin Mol Hepatol.
- 2023 Jan;29(1):173-175.
- doi: 10.3350/cmh.2022.0372
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
-
Liu Y, Chen M
- KMID: 2538212
- Clin Mol Hepatol.
- 2023 Jan;29(1):163-164.
- doi: 10.3350/cmh.2022.0326
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
-
Mak LY, Seto WK, Yuen MF
- KMID: 2538223
- Clin Mol Hepatol.
- 2023 Jan;29(1):191-193.
- doi: 10.3350/cmh.2022.0410
-
- CITED
-
- Close
- SHARE
-
- Close
- New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
-
Lim YS
- KMID: 2538208
- Clin Mol Hepatol.
- 2023 Jan;29(1):118-119.
- doi: 10.3350/cmh.2022.0413
-
- CITED
-
- Close
- SHARE
-
- Close
- Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
-
Gómez-Medina C, Melo L, Martí-Aguado D, Bataller R
- KMID: 2538197
- Clin Mol Hepatol.
- 2023 Jan;29(1):1-15.
- doi: 10.3350/cmh.2022.0017
Alcohol-related liver disease (ALD) consists of a wide spectrum of clinical manifestations and pathological features, ranging from asymptomatic patients to decompensated cirrhosis and hepatocellular carcinoma. Patients with heavy alcohol intake... -
- CITED
-
- Close
- SHARE
-
- Close
- Epidemiology and updated management for autoimmune liver disease
-
Heo NY, Kim H
- KMID: 2538224
- Clin Mol Hepatol.
- 2023 Jan;29(1):194-196.
- doi: 10.3350/cmh.2022.0387
-
- CITED
-
- Close
- SHARE
-
- Close
- Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
-
Liang LY, Wong VWS, Wong GLH, Yip TCF
- KMID: 2538207
- Clin Mol Hepatol.
- 2023 Jan;29(1):113-117.
- doi: 10.3350/cmh.2022.0333
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
-
Lee HW
- KMID: 2538215
- Clin Mol Hepatol.
- 2023 Jan;29(1):169-170.
- doi: 10.3350/cmh.2022.0384
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
-
Lee SM, Jun DW
- KMID: 2538216
- Clin Mol Hepatol.
- 2023 Jan;29(1):171-172.
- doi: 10.3350/cmh.2022.0381
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
-
Cheung KS, Mok CH, Seto WK, Yuen MF
- KMID: 2538218
- Clin Mol Hepatol.
- 2023 Jan;29(1):176-178.
- doi: 10.3350/cmh.2022.0377
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
-
Sohn W, Paik YH
- KMID: 2538220
- Clin Mol Hepatol.
- 2023 Jan;29(1):182-184.
- doi: 10.3350/cmh.2022.0411
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
-
Lee JH, Park K, Lee HS, Park HK, Han JH, Ahn SB
- KMID: 2538221
- Clin Mol Hepatol.
- 2023 Jan;29(1):185-187.
- doi: 10.3350/cmh.2022.0375
-
- CITED
-
- Close
- SHARE
-
- Close
- Management of refractory ascites
-
Wong F
- KMID: 2538198
- Clin Mol Hepatol.
- 2023 Jan;29(1):16-32.
- doi: 10.3350/cmh.2022.0104
The development of refractory ascites in approximately 10% of patients with decompensated cirrhosis heralds the progression to a more advanced stage of cirrhosis. Its pathogenesis is related to significant hemodynamic... -
- CITED
-
- Close
- SHARE
-
- Close
